menu
    • menu
    [{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Beijing Shenogen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"DI-LEU16-IL2","moa":"CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alopexx Oncology \/ Beijing Shenogen Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Alopexx Oncology \/ Beijing Shenogen Pharma"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Biotech Consortia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"AV0328","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alopexx Oncology \/ Biotech Consortia","highestDevelopmentStatusID":"14","companyTruncated":"Alopexx Oncology \/ Biotech Consortia"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"AV0328","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alopexx Oncology \/ Bharat Biotech","highestDevelopmentStatusID":"14","companyTruncated":"Alopexx Oncology \/ Bharat Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Alopexx Oncology

    Menu

    Alopexx Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alopexx Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alopexx Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV0328

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bharat Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Alopexx Collaborates with Bharat Biotech on Anti-Microbial Vaccine AV0328

                            Details : The collaboration aims for the co-development and commercialization of Alopexx’s proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low and lower middle-income countries.

                            Brand Name : AV0328

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : AV0328

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bharat Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alopexx Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alopexx Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV0328

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Biotech Consortia

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Alopexx Announces Investment from Biotech Consortia, Inc.

                            Details : The investment from BCI will be crucial for the advancement of AV0328, a synthetic vaccine designed to target poly N-acetyl glucosamine, and all clinical programs at Alopexx.

                            Brand Name : AV0328

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 06, 2024

                            Lead Product(s) : AV0328

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Biotech Consortia

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alopexx Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Alopexx Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DI-LEU16-IL2

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Beijing Shenogen Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma

                            Details : The deal facilitates development and commercialization of DI-Leu16-IL2 in China and other parts of Asia.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 03, 2020

                            Lead Product(s) : DI-LEU16-IL2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Beijing Shenogen Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth